Ramanathan, R. K., McDonough, S. L., Kennecke, H. F., Iqbal, S., Baranda, J. C., Seery, T. E., . . . Blanke, C. D. (2015). Phase 2 Study of MK-2206, an Allosteric Inhibitor of AKT, as Second-Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer: A SWOG Cooperative Group Trial (S1005). Cancer.
استشهاد بنمط شيكاغوRamanathan, Ramesh K., et al. "Phase 2 Study of MK-2206, an Allosteric Inhibitor of AKT, As Second-Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer: A SWOG Cooperative Group Trial (S1005)." Cancer 2015.
MLA استشهادRamanathan, Ramesh K., et al. "Phase 2 Study of MK-2206, an Allosteric Inhibitor of AKT, As Second-Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer: A SWOG Cooperative Group Trial (S1005)." Cancer 2015.